MedTrace Logo

Computational Drug Repurposing for All EBS Cases

NCT03269474 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-02-13

No results posted yet for this study

Summary

The study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State of the art computational analysis will be performed to help identify new drugs that might help all EB wound healing and reduce pain. Researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of EB. Drug development is a very expensive process taking decades for execution. Drug repurposing on the other hand, significantly reduces the cost and shortens the amount of time that is needed to bring effective treatments to clinical use. To date, there is no specific treatment targeting the physiology and immunologic response in EB patients during wound healing. Market availability of repurposed medications will provide all EB patients rapid access to treatments, thus improving their quality of life.

Conditions

  • Epidermolysis Bullosa
  • Healthy
  • Genetic Skin Disease
  • Epidermolysis Bullosa Simplex
  • Epidermolysis Bullosa, Junctional
  • Epidermolysis Bullosa Dystrophica

Interventions

PROCEDURE

Experimental Group

Subjects with EB diagnosis

Sponsors & Collaborators

  • Joyce Teng

    lead OTHER

Principal Investigators

  • Joyce M Teng, MD, PhD · Stanford University

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2024-12-30
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03269474 on ClinicalTrials.gov